WO1998022494A3 - METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS - Google Patents

METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS Download PDF

Info

Publication number
WO1998022494A3
WO1998022494A3 PCT/US1997/020804 US9720804W WO9822494A3 WO 1998022494 A3 WO1998022494 A3 WO 1998022494A3 US 9720804 W US9720804 W US 9720804W WO 9822494 A3 WO9822494 A3 WO 9822494A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthesis
amyloid peptide
compounds
methods
peptide release
Prior art date
Application number
PCT/US1997/020804
Other languages
French (fr)
Other versions
WO1998022494A9 (en
WO1998022494A2 (en
Inventor
James E Audia
Thomas C Britton
James J Droste
Beverly K Folmer
George W Huffman
Varghese John
Lee H Latimer
Thomas E Mabry
Jeffrey S Nissen
Warren J Porter
Jon K Reel
Eugene D Thorsett
Jay S Tung
Jing Wu
Clark Norman Eid
William Leonard Scott
Original Assignee
Athena Neurosciences Inc
Lilly Co Eli
James E Audia
Thomas C Britton
James J Droste
Beverly K Folmer
George W Huffman
Varghese John
Lee H Latimer
Thomas E Mabry
Jeffrey S Nissen
Warren J Porter
Jon K Reel
Eugene D Thorsett
Jay S Tung
Jing Wu
Clark Norman Eid
William Leonard Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR9713400-7A priority Critical patent/BR9713400A/en
Priority to EP97950601A priority patent/EP0942924A2/en
Priority to EA199900490A priority patent/EA199900490A1/en
Priority to CA002267634A priority patent/CA2267634A1/en
Priority to HU0100270A priority patent/HUP0100270A3/en
Priority to JP52375698A priority patent/JP2001503782A/en
Application filed by Athena Neurosciences Inc, Lilly Co Eli, James E Audia, Thomas C Britton, James J Droste, Beverly K Folmer, George W Huffman, Varghese John, Lee H Latimer, Thomas E Mabry, Jeffrey S Nissen, Warren J Porter, Jon K Reel, Eugene D Thorsett, Jay S Tung, Jing Wu, Clark Norman Eid, William Leonard Scott filed Critical Athena Neurosciences Inc
Priority to IL12908397A priority patent/IL129083A0/en
Priority to AU53561/98A priority patent/AU5356198A/en
Publication of WO1998022494A2 publication Critical patent/WO1998022494A2/en
Publication of WO1998022494A9 publication Critical patent/WO1998022494A9/en
Publication of WO1998022494A3 publication Critical patent/WO1998022494A3/en
Priority to NO992368A priority patent/NO992368L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
PCT/US1997/020804 1996-11-22 1997-11-21 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS WO1998022494A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP97950601A EP0942924A2 (en) 1996-11-22 1997-11-21 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
EA199900490A EA199900490A1 (en) 1996-11-22 1997-11-21 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE ALLOCATION AND / OR ITS SYNTHESIS
CA002267634A CA2267634A1 (en) 1996-11-22 1997-11-21 Methods and compounds for inhibiting .beta.-amyloid peptide release and/or synthesis
HU0100270A HUP0100270A3 (en) 1996-11-22 1997-11-21 Peptids for inhibiting betha-amyloid peptide release and/or its synthesis, pharmaceutical compositions comprising thereof and their use
JP52375698A JP2001503782A (en) 1996-11-22 1997-11-21 Method and compound for inhibiting release of beta-amyloid peptide and / or its synthesis
BR9713400-7A BR9713400A (en) 1996-11-22 1997-11-21 Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.
IL12908397A IL129083A0 (en) 1996-11-22 1997-11-21 Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU53561/98A AU5356198A (en) 1996-11-22 1997-11-21 Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
NO992368A NO992368L (en) 1996-11-22 1999-05-14 Methods and Compounds for Inhibiting <beta> -amyloid Release and / or its Synthesis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US75544296A 1996-11-22 1996-11-22
US08/755,442 1996-11-22
US80852897A 1997-02-28 1997-02-28
US80752897A 1997-02-28 1997-02-28
US80742797A 1997-02-28 1997-02-28
US08/807,427 1997-02-28
US08/807,528 1997-02-28
US08/808,528 1997-02-28

Publications (3)

Publication Number Publication Date
WO1998022494A2 WO1998022494A2 (en) 1998-05-28
WO1998022494A9 WO1998022494A9 (en) 1998-08-20
WO1998022494A3 true WO1998022494A3 (en) 1998-11-26

Family

ID=27505670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020804 WO1998022494A2 (en) 1996-11-22 1997-11-21 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS

Country Status (21)

Country Link
EP (1) EP0942924A2 (en)
JP (1) JP2001503782A (en)
KR (1) KR20000069064A (en)
CN (1) CN1238779A (en)
AR (1) AR016751A1 (en)
AU (1) AU5356198A (en)
BR (1) BR9713400A (en)
CA (1) CA2267634A1 (en)
CO (1) CO4910156A1 (en)
CZ (1) CZ122899A3 (en)
EA (1) EA199900490A1 (en)
HR (1) HRP970627A2 (en)
HU (1) HUP0100270A3 (en)
ID (1) ID22044A (en)
IL (1) IL129083A0 (en)
NO (1) NO992368L (en)
NZ (1) NZ334690A (en)
PE (1) PE16999A1 (en)
TR (3) TR199901133T2 (en)
WO (1) WO1998022494A2 (en)
YU (1) YU46097A (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (en) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
JP2002518483A (en) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド Compounds for inhibiting β-amyloid peptide release and / or their synthesis
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2002518451A (en) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド Cyclic amino acid compound and pharmaceutical composition thereof, and method of inhibiting release of β-amyloid peptide and / or synthesis thereof using the compound
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
AU6278099A (en) 1998-09-30 2000-04-17 Elan Pharmaceuticals, Inc. Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CA2352740A1 (en) 1998-12-10 2000-06-15 F. Hoffmann-La Roche Ag Procollagen c-proteinase inhibitors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
ATE277923T1 (en) * 1999-05-07 2004-10-15 Texas Biotechnology Corp PROPANE ACID DERIVATIVES THAT PREVENT THE BINDING OF INTEGRINS TO THEIR RECEPTORS
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
WO2001034639A2 (en) * 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
CA2400226C (en) 2000-03-31 2007-01-02 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
FR2832152A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
AR039059A1 (en) * 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
DE10143840A1 (en) * 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
IL161841A0 (en) 2001-11-09 2005-11-20 Aventis Pharma Sa 2-Amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
PL372316A1 (en) 2002-02-28 2005-07-11 Prosidion Limited Glutaminyl based dpiv inhibitors
KR101076018B1 (en) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 Antibacterial agents
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
DE602004026712D1 (en) 2003-05-05 2010-06-02 Probiodrug Ag MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES
EP1666068A4 (en) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd Remedy for eye diseases accompanied by optic nerve injuries
MXPA06003998A (en) 2003-10-15 2006-06-27 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases.
TWI519508B (en) 2007-06-12 2016-02-01 Achaogen Inc Antibacterial agents
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
BG110141A (en) 2008-05-23 2009-12-31 "Софарма" Ад Galanthamine derivatives, methods for their obtaining and use
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
WO2017004560A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
WO2022150314A1 (en) * 2021-01-05 2022-07-14 Southern Research Institute Modulators of programmed death-ligand-1

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009838A1 (en) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION
EP0652009A1 (en) * 1993-08-09 1995-05-10 Eli Lilly And Company Identification and use of protease inhibitors
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
WO1996020725A2 (en) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
WO1996020949A1 (en) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
EP0732399A2 (en) * 1990-03-05 1996-09-18 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
WO1996039194A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0732399A2 (en) * 1990-03-05 1996-09-18 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
EP0652009A1 (en) * 1993-08-09 1995-05-10 Eli Lilly And Company Identification and use of protease inhibitors
WO1995009838A1 (en) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION
WO1996020725A2 (en) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
WO1996020949A1 (en) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
WO1996039194A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAPADOPOULOS A ET AL: "ANODIC OXIDATION OF N-ACYL AND N-ALKOXYCARBONYL DIPEPTIDE ESTERS ASA KEY STEP FOR THE FORMATION OF CHIRAL HETEROCYCLIC SYNTHETIC BUILDING BLOCKS", TETRAHEDRON, vol. 47, no. 4/05, 28 January 1991 (1991-01-28), pages 563 - 572, XP000565601 *

Also Published As

Publication number Publication date
KR20000069064A (en) 2000-11-25
NO992368D0 (en) 1999-05-14
YU46097A (en) 2000-10-30
ID22044A (en) 1999-08-26
TR199902938T2 (en) 2002-06-21
PE16999A1 (en) 1999-02-19
CZ122899A3 (en) 1999-10-13
BR9713400A (en) 2000-01-25
CN1238779A (en) 1999-12-15
CO4910156A1 (en) 2000-04-24
EP0942924A2 (en) 1999-09-22
AU5356198A (en) 1998-06-10
IL129083A0 (en) 2000-02-17
HUP0100270A3 (en) 2001-09-28
TR199902937T2 (en) 2001-01-22
NZ334690A (en) 2001-09-28
EA199900490A1 (en) 2000-02-28
AR016751A1 (en) 2001-08-01
NO992368L (en) 1999-06-21
WO1998022494A2 (en) 1998-05-28
JP2001503782A (en) 2001-03-21
CA2267634A1 (en) 1998-05-28
HUP0100270A2 (en) 2001-08-28
TR199901133T2 (en) 1999-07-21
HRP970627A2 (en) 1998-08-31

Similar Documents

Publication Publication Date Title
WO1998022494A3 (en) METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS
WO1998028268A3 (en) CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO1998022493A3 (en) N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
AU5249898A (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1998022441A3 (en) N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide and/or its synthesis
WO2002047671A3 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
CA2284170A1 (en) Identification of agents for use in the treatment of alzheimer&#39;s disease
CA2289531A1 (en) Composition and methods for treating alzheimer&#39;s disease and other amyloidoses
NO994016L (en) Heterocyclic Compounds and Their Use for Inhibition of &lt;beta&gt; Amyloid Peptide
AU2001273132A1 (en) Compounds to treat alzheimer&#39;s disease
PL344861A1 (en) Trazinic angiogenesis inhibitiors
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer&#39;s disease
CA2383983A1 (en) Substituted indolealkanoic acids
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
WO1999040112A8 (en) Neuroprotective peptides and uses thereof
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer&#39;s disease.
ZA9710272B (en) Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds.
CA2264268A1 (en) Novel peptide derivatives having thiazolyl-alanine residue
CA2283255A1 (en) Use of r-nsaid&#39;s for the prevention of alzheimer&#39;s disease
BG104179A (en) Phanquinon administration for the treatment of the alzheimer&#39;s disease
CA2116829A1 (en) Use of a pregnane derivative
WO2000021550A3 (en) Methods and compositions for treating neurodegenerative diseases
AU1405899A (en) Treatment for alzheimer&#39;s disease
AU1496597A (en) 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer&#39;s Disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199803.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1-378, DESCRIPTION, REPLACED BY NEW PAGES 1-378; PAGES 379-485, CLAIMS, REPLACED BY NEW PAGES 379-485; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 334690

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 53561/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2267634

Country of ref document: CA

Ref document number: 2267634

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-1228

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1998 523756

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1199900395

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004744

Country of ref document: MX

Ref document number: 1019997004486

Country of ref document: KR

Ref document number: 1999/01133

Country of ref document: TR

Ref document number: P-228/99

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 1997950601

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997950601

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-1228

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1999/02938

Country of ref document: TR

Ref document number: 1999/02937

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1019997004486

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019997004486

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997950601

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1999-1228

Country of ref document: CZ